title: Differences between sporadic and MEN related primary hyperparathyroidism; clinical expression, preoperative workup, operative strategy and follow-up.
abstract: BACKGROUND
  Primary hyperparathyroidism (PHPT) is most commonly sporadic (sPHPT). However, sometimes PHPT develops as part of multiple endocrine neoplasia (MEN) type 1 or 2A. In all, parathyroidectomy is the only curative treatment. Nevertheless, there are important differences in clinical expression and treatment.
  
  
  METHODS
  We analyzed a consecutive cohort of patients treated for sporadic, MEN1-related, and MEN2A-related PHPT and compared them regarding clinical and biochemical parameters, differences in preoperative workup, operative strategies, findings, and outcome.
  
  
  RESULTS
  A total of 467 patients with sPHPT, 52 with MEN1- and 16 with MEN2A-related PHPT were analyzed. Patients with sPHPT were older, more often female and had higher preoperative calcium and parathyroid hormone levels, when compared with MEN1 and MEN2A patients. Minimally invasive parathyroidectomy (MIP) was performed in 367 of 467 sPHPT patients (79%). One abnormal parathyroid was found in 426 patients (91%). Two or more in 35 patients (7%). In six patients (1%) no abnormal parathyroid gland was retrieved. Of 52 MEN1 patients, eight (15%) underwent a MIP and 44 patients (85%) underwent conventional neck exploration (CNE); with resection of fewer than 3½ enlarged glands in 21 patients (40%), subtotal parathyroidectomy (SPTX, 3-3½ glands) in seventeen (33%) and total parathyroidectomy with autotransplantation (TPTX) in six (12%). Eleven patients (21%) had persistent disease, 29 (56%) recurrent PHPT and nine (17%) permanent hypoparathyroidism, mostly after TPTX. Of 16 MEN2A patients, six (38%) underwent MIP, four (25%) CNE and six (38%) selective resection of the enlarged gland(s) during total thyroidectomy. Three patients (19%) suffered from persistent PHPT and two (13%) developed recurrent disease.
  
  
  CONCLUSIONS
  Sporadic PHPT, MEN1- and MEN2A-related PHPT are three distinct entities as is reflected preoperatively by differences in gender, age at diagnosis and calcium and PTH levels. MEN2A patients are very similar to sPHPT with respect to operative approach and findings. MIP is the treatment of choice for both. MIP has low rates of persistent and recurrent PHPT and a low complication rate. The percentage of multiglandular disease and recurrences are significantly higher in MEN1 patients, demonstrating the need for a different approach. We advocate treating these patients with CNE and SPTX.
authors.affiliation: Department of Surgical Oncology and Endocrine Surgery, University Medical Center, Utrecht, 3584CX, the Netherlands.
authors.forename: Bas A
authors.initials: BA
authors.lastname: Twigt
authors.forename: Anouk
authors.initials: A
authors.lastname: Scholten
authors.forename: Gerlof D
authors.initials: GD
authors.lastname: Valk
authors.forename: Inne H M Borel
authors.initials: IH
authors.lastname: Rinkes
authors.forename: Menno R
authors.initials: MR
authors.lastname: Vriens
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006980:Hyperthyroidism / Q000175:diagnosis / Q000235:genetics / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D018813:Multiple Endocrine Neoplasia Type 2a / Q000235:genetics*; D011300:Preoperative Care; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: C105373:MEN1 protein, human; D011518:Proto-Oncogene Proteins
references.citation: Surgery. 1998 Dec;124(6):993-9
references.pmid: 9854574
references.citation: J Bone Miner Res. 2002 Nov;17 Suppl 2:N37-43
references.pmid: 12412776
references.citation: J Am Coll Surg. 2006 Jul;203(1):1-6
references.pmid: 16798481
references.citation: J Clin Endocrinol Metab. 2003 Oct;88(10):4641-8
references.pmid: 14557434
references.citation: J Am Coll Surg. 2003 Apr;196(4):535-40
references.pmid: 12691927
references.citation: Surgery. 1998 Dec;124(6):1106-13; discussion 1113-4
references.pmid: 9854591
references.citation: Am J Surg. 2006 Jan;191(1):52-6
references.pmid: 16399106
references.citation: Arch Surg. 2006 Mar;141(3):235-9
references.pmid: 16549687
references.citation: N Engl J Med. 1994 Sep 29;331(13):828-35
references.pmid: 7915822
references.citation: Arq Bras Endocrinol Metabol. 2010 Mar;54(2):106-9
references.pmid: 20485897
references.citation: Ann Surg Oncol. 2006 Jan;13(1):103-9
references.pmid: 16378158
references.citation: J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71
references.pmid: 11739416
references.citation: Ann Surg. 2012 Jun;255(6):1171-8
references.pmid: 22470073
references.citation: Am J Surg. 2012 Jul;204(1):1-6
references.pmid: 22192616
references.citation: Arch Surg. 2002 Aug;137(8):896-9; discussion 899-900
references.pmid: 12146987
references.citation: Arch Surg. 2005 Apr;140(4):374-82
references.pmid: 15841561
references.citation: Ann Surg. 2000 Apr;231(4):559-65
references.pmid: 10749618
references.citation: J Bone Miner Res. 2010 Nov;25(11):2382-91
references.pmid: 20499354
references.citation: Surgery. 2005 Oct;138(4):583-7; discussion 587-90
references.pmid: 16269285
references.citation: Biomed Pharmacother. 2000 Jun;54 Suppl 1:21s-24s
references.pmid: 10914986
references.citation: Eur J Endocrinol. 2012 Aug;167(2):181-7
references.pmid: 22581216
references.citation: Surgery. 2003 Dec;134(6):858-64; discussion 864-5
references.pmid: 14668715
references.citation: Ann Surg. 2007 Dec;246(6):1075-82
references.pmid: 18043113
references.citation: Horm Metab Res. 2001 Aug;33(8):499-503
references.pmid: 11544565
references.citation: World J Surg. 2002 Aug;26(8):921-5
references.pmid: 12016471
references.citation: Otolaryngol Clin North Am. 2004 Aug;37(4):715-36, viii
references.pmid: 15262511
references.citation: Am J Med. 1979 Mar;66(3):422-4
references.pmid: 34999
references.citation: World J Surg. 2004 Nov;28(11):1127-31
references.pmid: 15490069
references.citation: Miner Electrolyte Metab. 1984;10(5):301-8
references.pmid: 6493158
references.citation: World J Surg. 2011 Sep;35(9):1993-2005
references.pmid: 21713580
references.citation: Clin Endocrinol (Oxf). 2007 Jun;66(6):878-85
references.pmid: 17437518
references.citation: Surgery. 2003 Dec;134(6):973-9; discussion 979-81
references.pmid: 14668730
references.citation: World J Surg. 1992 Jul-Aug;16(4):718-22; discussion 722-3
references.pmid: 1357833
references.citation: Biomed Pharmacother. 2000 Jun;54 Suppl 1:86s-89s
references.pmid: 10915000
references.citation: Ann Surg Oncol. 2011 Apr;18(4):1041-6
references.pmid: 21174159
references.citation: Br J Surg. 2007 Mar;94(3):315-9
references.pmid: 17205496
references.citation: World J Surg. 2004 Dec;28(12):1287-92
references.pmid: 15517474
references.citation: World J Surg. 1986 Aug;10(4):668-72
references.pmid: 2875566
references.citation: Arch Otolaryngol Head Neck Surg. 2004 Jan;130(1):87-91
references.pmid: 14732775
references.citation: Langenbecks Arch Surg. 2009 Sep;394(5):843-9
references.pmid: 19529957
references.citation: Arch Surg. 1998 Feb;133(2):126-9
references.pmid: 9484721
references.citation: Br J Surg. 2007 Jan;94(1):42-7
references.pmid: 17083106
references.citation: J Bone Miner Res. 2009 Aug;24(8):1404-10
references.pmid: 19309299
references.citation: J Am Coll Surg. 2007 Feb;204(2):286-90
references.pmid: 17254933
references.citation: Ann Surg. 1999 Jun;229(6):874-8; discussion 878-9
references.pmid: 10363902
references.citation: Endocr Pract. 2011 Jan-Feb;17(1):7-15
references.pmid: 20570815
references.citation: J Bone Miner Res. 1991 Oct;6 Suppl 2:S25-30; discussion S31-2
references.pmid: 1763669